How Sites Can Win in the New Age of Genetically Engineered Treatments
The accelerating gene therapy market is expected to grow 16.6 percent by 2027. As gene therapies enter the pipeline, how can sites prepare themselves to take advantage of the rush?
Biosafety, Ethical, and Logistical Challenges to Pursuing a Coronavirus Vaccine at Warp Speed
The SARS-CoV-2 pandemic has impacted all aspects of society. Various government and private groups around the world are endeavoring to develop safe and effective vaccines at an unprecedented pace and scale to quell the pandemic as quickly as possible.
mRNA and Its Role in Clinical Research
Messenger RNA (mRNA) has made recent headlines due to its role in Operation Warp Speed. This article explores how its technology is used to fight the COVID-19 pandemic.
Does Warp Speed Vaccine Development and Testing Compromise Safety?
Fiction often shows warp speed travels not going as planned, but what does warp speed mean for vaccine development in clinical research?
By the Numbers: Our Response to COVID-19
We are honored to support a resilient research community during the COVID-19 pandemic. Explore our resources to find out how we keep research moving forward.
Institutional Biosafety Committee Reviews 101
What is an IBC? How long does an IBC review take? Read our IBC 101 handout to get answers to some of your most frequently asked questions.
Q&A – Study Startup Success for the New Generation of Genetically Engineered Vaccines
Daniel Eisenman answers questions from his latest webinar Study Startup Success for the New Generation of Genetically Engineered Vaccines.